Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;4(1):4-9.
doi: 10.4103/2229-5070.129142.

Drug resistance in leishmaniasis: Newer developments

Sarita Mohapatra  1
Affiliations
Review

Drug resistance in leishmaniasis: Newer developments

Sarita Mohapatra. Trop Parasitol. 2014 Jan.

Abstract

Leishmaniasis is a vector borne protozoan disease and it remains a major public health problem world-wide. Lack of an effective vaccine and vector control program makes the chemotherapy as the primary tool for leishmaniasis. Antimonials were used as the first line of treatment for many years. Emergence of resistance against this drug has become a major concern. Literatures and studies published on anti-leishmanial drug resistance, newer drug discovery for leishmanial resistance etc., in PubMed, Medline and Google search and reviewed thoroughly. Various newer drugs have been identified but, are in limited use because of high cost, toxicity, resistance etc., Recently, many newer mechanisms of drug resistance have been identified which may boost in future designing and development of drugs.

Keywords: Amphotericin B; antimonials; drug resistance; leishmaniasis; miltefocine; paromomycin.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Singh S. New developments in diagnosis of leishmaniasis. Indian J Med Res. 2006;123:311–30. - PubMed
    1. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111–26. - PMC - PubMed
    1. Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res. 2006;123:411–22. - PubMed
    1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873–82. - PubMed
    1. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739–46. - PubMed